Companies in #NASH (Non-Alcoholic Steatohepatitis)
Found 1 company operating in this sector.
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company that developed and commercialized Rezdiffra (resmetirom), the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-severe liver fibrosis. The company is now pursuing expanded indications and next-generation oral small-molecule therapeutics for liver and metabolic diseases.